Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.sightsciences.com, in the News & Events section.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Staff

Recent Posts

Yuwell Medical Makes Its Debut at CES 2026: AI Expands the Boundaries of Health Management

LAS VEGAS, Jan. 8, 2026 /PRNewswire/ -- From January 6 to 9, CES 2026, held in…

5 hours ago

Proximity Health Solutions and Biogen Named Finalists for the SCOPE ’26 Participant Engagement Award

STAMFORD, Conn., Jan. 8, 2026 /PRNewswire/ -- Proximity Health Solutions, in collaboration with Biogen, announces that…

11 hours ago

In HelloNation, Personal Injury Attorney Professional Joseph Miklos of Garden City, NY, Launches New Expert Website Highlighting His Work in the Community

GARDEN CITY, N.Y., Jan. 8, 2026 /PRNewswire/ -- What defines a Personal Injury Attorney Professional…

11 hours ago

Therap’s Individual Home Page Integrates Person-Centered Data for Comprehensive Care Management

TORRINGTON, Conn., Jan. 8, 2026 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

11 hours ago

FUGO Precision 3D and Graphy Forge Strategic Partnership to Accelerate Advanced Material Integration Ahead of LMT 2026 Launch

GARDENA, Calif., Jan. 8, 2026 /PRNewswire/ -- FUGO Precision 3D, a pioneering force in next-generation…

11 hours ago